Aminofenoler
Filtrerade sökresultat
ZL0420, MedChemExpress
MedChemExpress ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C16H16N4O2 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 296.32 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : 125 mg/mL (421.84 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Orange |
| CAS | 2230496-80-5 |
| LEDER | OC1=CC(N)=C(/N=N/C2=CC(CCC(N3)=O)=C3C=C2)C=C1C.[(E)] |
| Molekylvikt (g/mol) | 296.32 |
| Kemiskt namn eller material | ZL0420 |
| Procent renhet | 98.0% |
| För användning med (applikation) | COVID-19-immunoregulation |
BN82002, MedChemExpress
MedChemExpress BN82002 is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 μM, respectively. BN82002 displays ∼20-fold greater selectivity over CD45 tyrosine phosphatase.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C19H25N3O4 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 359.42 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : ≥ 150 mg/mL (417.34 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Yellow |
| CAS | 396073-89-5 |
| LEDER | OC1=C(CN(C)CCC2=CC=C([N+]([O-])=O)C=C2)C=C(N(C)C)C=C1OC |
| Molekylvikt (g/mol) | 359.42 |
| Kemiskt namn eller material | BN82002 |
| För användning med (applikation) | Cancer-programmed cell death |
OTS514, MedChemExpress
MedChemExpress OTS514 is a highly potent TOPK inhibitor with an IC50 of 2.6 nM. OTS514 strongly suppresses the growth of TOPK-positive cancer cells. OTS514 induces cell cycle arrest and apoptosis.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C21H20N2O2S |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 364.46 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : 100 mg/mL (274.38 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Earth Yellow |
| CAS | 1338540-63-8 |
| LEDER | O=C1NC2=C(C(C3=CC=C([C@@H](C)CN)C=C3)=C(O)C=C2C)C4=C1SC=C4 |
| Molekylvikt (g/mol) | 364.46 |
| Kemiskt namn eller material | OTS514 |
| Procent renhet | 98.15% |
| För användning med (applikation) | Cancer-Kinase/protease |
Acetaminophen metabolite 3-hydroxy-acetaminophen, MedChemExpress
MedChemExpress 3-hydroxy-acetaminophen is a metabolite of Acetaminophen, which is a pain medicine.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C8H9NO3 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 167.16 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Hälsofara 1 | H302∣H315∣H319∣H335 |
| Löslighetsinformation | DMSO : 250 mg/mL (1495.57 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Gray |
| CAS | 37519-14-5 |
| LEDER | OC1=C(O)C=C(NC(C)=O)C=C1 |
| Molekylvikt (g/mol) | 167.16 |
| Synonym | 3-Hydroxyacetaminophen |
| Kemiskt namn eller material | Acetaminophen metabolite 3-hydroxy-acetaminophen |
| Procent renhet | 99.03% |
| För användning med (applikation) | Neuroscience-Neuromodulation |
inS3-54A18, MedChemExpress
MedChemExpress inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C23H16ClNO2 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 373.83 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : ≥ 150 mg/mL (401.25 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Orange |
| CAS | 328998-53-4 |
| LEDER | O=C1N(C2=CC=C(O)C=C2)C(C3=CC=CC=C3)=C/C1=C/C4=CC=C(Cl)C=C4 |
| Molekylvikt (g/mol) | 373.83 |
| Kemiskt namn eller material | inS3-54A18 |
| Procent renhet | 99.83% |
| För användning med (applikation) | Cancer-Kinase/protease |
Lavendustin A, MedChemExpress
MedChemExpress Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of tyrosine kinase, with an IC50 of 11 ng/mL for EGFR-associated tyrosine kinase. It suppresses VEGF-induced angiogenesis and blocks the induction of LTPGABA-A.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C21H19NO6 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 381.38 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : ≥ 250 mg/mL (655.51 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Off-White |
| CAS | 125697-92-9 |
| LEDER | O=C(O)C1=CC(N(CC2=CC(O)=CC=C2O)CC3=CC=CC=C3O)=CC=C1O |
| Molekylvikt (g/mol) | 381.38 |
| Synonym | RG-14355 |
| Kemiskt namn eller material | Lavendustin A |
| Procent renhet | 95.0% |
| För användning med (applikation) | Cancer-Kinase/protease |
SKI II, MedChemExpress
MedChemExpress SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C15H11ClN2OS |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 302.78 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Hälsofara 1 | H302 |
| Löslighetsinformation | DMSO : ≥ 100 mg/mL (330.27 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | White |
| CAS | 312636-16-1 |
| LEDER | OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1 |
| Molekylvikt (g/mol) | 302.78 |
| Kemiskt namn eller material | SKI II |
| Procent renhet | 99.88% |
| För användning med (applikation) | Cancer-Kinase/protease |
Propyl pyrazole triol, MedChemExpress
MedChemExpress Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%).
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
Balsalazide, MedChemExpress
MedChemExpress Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C17H15N3O6 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 357.32 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : 100 mg/mL (279.86 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Orange |
| CAS | 80573-04-2 |
| LEDER | O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O |
| Molekylvikt (g/mol) | 357.32 |
| Kemiskt namn eller material | Balsalazide |
| Procent renhet | 99.2% |
| För användning med (applikation) | COVID-19-immunoregulation |
S55746, MedChemExpress
MedChemExpress S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C43H42N4O6 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 710.82 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : 50 mg/mL (70.34 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Powder |
| Kvalitet | Research |
| Färg | Light Yellow |
| CAS | 1448584-12-0 |
| LEDER | O=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9 |
| Molekylvikt (g/mol) | 710.82 |
| Synonym | BCL201 |
| Kemiskt namn eller material | S55746 |
| Procent renhet | 98.93% |
| För användning med (applikation) | Cancer-programmed cell death |
Fenretinide, MedChemExpress
MedChemExpress Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C26H33NO2 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 391.55 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Hälsofara 1 | H302+H312+H332∣H315∣H319∣H335∣H360 |
| Löslighetsinformation | DMSO : ≥ 130 mg/mL (332.01 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Yellow |
| CAS | 65646-68-6 |
| LEDER | CC(/C=C/C=C(/C=C/C1=C(CCCC(C)1C)C)C)=C\C(NC2=CC=C(O)C=C2)=O |
| Molekylvikt (g/mol) | 391.55 |
| Synonym | 4-HPR |
| Kemiskt namn eller material | Fenretinide |
| Procent renhet | 99.08% |
| För användning med (applikation) | Cancer-programmed cell death |
Osalmid, MedChemExpress
MedChemExpress Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 μM.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C13H11NO3 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 229.23 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Hälsofara 1 | H302∣H315∣H319 |
| Löslighetsinformation | DMSO : ≥ 100 mg/mL (436.24 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Off-White |
| CAS | 526-18-1 |
| LEDER | O=C(NC1=CC=C(O)C=C1)C2=CC=CC=C2O |
| Molekylvikt (g/mol) | 229.23 |
| Synonym | Oxaphenamide 4'-Hydroxysalicylanilide |
| Kemiskt namn eller material | Osalmid |
| Procent renhet | 99.85% |
| För användning med (applikation) | COVID-19-anti-virus |
S55746 hydrochloride, MedChemExpress
MedChemExpress S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C43H43ClN4O6 |
|---|---|
| Rekommenderad förvaring | 4°C, stored under nitrogen∣In solvent : -80°C, 6 months∣-20°C, 1 month (stored under nitrogen) |
| Formel vikt | 747.28 |
| Hållbarhet | 4°C, stored under nitrogen∣In solvent : -80°C, 6 months∣-20°C, 1 month (stored under nitrogen) |
| Löslighetsinformation | DMSO : 200 mg/mL (267.64 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Powder |
| Kvalitet | Research |
| Färg | Light Yellow |
| CAS | 1448525-91-4 |
| LEDER | O=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9.Cl |
| Molekylvikt (g/mol) | 747.28 |
| Synonym | BCL201 hydrochloride |
| Kemiskt namn eller material | S55746 hydrochloride |
| Procent renhet | 98.69% |
| För användning med (applikation) | Cancer-programmed cell death |
5-Lipoxygenase-In-1, MedChemExpress
MedChemExpress 5-Lipoxygenase-In-1 is a 5-Lipoxygenase inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C23H28N4O2S |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 424.56 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Löslighetsinformation | DMSO : 250 mg/mL (588.84 mM; Need ultrasonic) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Off-White |
| CAS | 125235-15-6 |
| LEDER | O=C(C(C)(C)N1CC)N(C2=CC=C(N3CCN(C4=CC=C(O)C=C4)CC3)C=C2)C1=S |
| Molekylvikt (g/mol) | 424.56 |
| Kemiskt namn eller material | 5-Lipoxygenase-In-1 |
| Procent renhet | 98.07% |
| För användning med (applikation) | COVID-19-immunoregulation |
JANEX-1, MedChemExpress
MedChemExpress JANEX-1 (WHI-P131) is a potent and specific JAK3 inhibitor (estimated Ki=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC50 of 78 μM), does not inhibit JAK1 and JAK2.
Non-distribution item offered as a customer accommodation; additional freight charges may apply.
Learn More
| Molekylformel | C16H15N3O3 |
|---|---|
| Rekommenderad förvaring | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Formel vikt | 297.31 |
| Hållbarhet | Powder -20°C 3 years, 4°C 2 years∣In solvent -80°C 6 months, -20°C 1 month |
| Hälsofara 1 | H302∣H315∣H319∣H335 |
| Löslighetsinformation | DMSO : ≥ 100 mg/mL (336.35 mM) |
| Anteckningar om renhetsgrad | Research |
| Fysisk form | Solid |
| Kvalitet | Research |
| Färg | Gray |
| CAS | 202475-60-3 |
| LEDER | OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1 |
| Molekylvikt (g/mol) | 297.31 |
| Synonym | WHI-P131 Jak3 inhibitor I |
| Kemiskt namn eller material | JANEX-1 |
| Procent renhet | 99.6% |
| För användning med (applikation) | Cancer-Kinase/protease |